Title
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma
Date Issued
11 March 2019
Access level
open access
Resource Type
review
Author(s)
Bousquet J.
Bedbrook A.
Czarlewski W.
Onorato G.L.
Arnavielhe S.
Laune D.
Mathieu-Dupas E.
Fonseca J.
Costa E.
Lourenço O.
Morais-Almeida M.
Todo-Bom A.
Illario M.
Menditto E.
Canonica G.W.
Cecchi L.
Monti R.
Napoli L.
Ventura M.T.
De Feo G.
Fokkens W.J.
Chavannes N.H.
Reitsma S.
Cruz A.A.
Da Silva J.
Serpa F.S.
Larenas-Linnemann D.
Fuentes Perez J.M.
Huerta-Villalobos Y.R.
Rivero-Yeverino D.
Rodriguez-Zagal E.
Valiulis A.
Dubakiene R.
Emuzyte R.
Kvedariene V.
Annesi-Maesano I.
Blain H.
Bonniaud P.
Bosse I.
Dauvilliers Y.
Devillier P.
Fontaine J.F.
Pépin J.L.
Pham-Thi N.
Portejoie F.
Picard R.
Roche N.
Rolland C.
Schmidt-Grendelmeier P.
Kuna P.
Samolinski B.
Anto J.M.
Cardona V.
Mullol J.
Pinnock H.
Ryan D.
Sheikh A.
Walker S.
Williams S.
Becker S.
Klimek L.
Pfaar O.
Bergmann K.C.
Mösges R.
Zuberbier T.
Roller-Wirnsberger R.E.
Tomazic P.V.
Haahtela T.
Salimäki J.
Toppila-Salmi S.
Valovirta E.
Vasankari T.
Gemicioǧlu B.
Yorgancioglu A.
Papadopoulos N.G.
Prokopakis E.P.
Tsiligianni I.G.
Bosnic-Anticevich S.
O'Hehir R.
Ivancevich J.C.
Neffen H.
Zernotti M.E.
Kull I.
Melén E.
Wickman M.
Bachert C.
Hellings P.W.
Brusselle G.
Palkonen S.
Bindslev-Jensen C.
Eller E.
Waserman S.
Boulet L.P.
Bouchard J.
Chu D.K.
Schünemann H.J.
Sova M.
De Vries G.
Van Eerd M.
Agache I.
Publisher(s)
John Wiley and Sons Inc
Abstract
Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors. Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.
Volume
9
Issue
1
Language
English
OCDE Knowledge area
Otorrinolaringología
Subjects
Scopus EID
2-s2.0-85062865821
Source
Clinical and Translational Allergy
ISSN of the container
20457022
Sponsor(s)
Dr. Ansotegui reports personal fees from Mundipharma, Roxall, Sanofi, MSD, Faes Farma, Hikma, UCB, Astra Zeneca, outside the submitted work. Dr. Bosnic‑ Anticevich reports grants from TEVA, personal fees from TEVA, Boehringer Ingelheim, AstraZeneca, Sanofi, Mylan, outside the submitted work. Dr Bousquet reports personal fees and others from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‑Aventis, Takeda, Teva, Uriach, others from Kyomed, outside the submitted work. Dr. Boulet reports and Disclosure of potential conflicts of interest—last 3 years research grants for participa‑ tion to multicentre studies, AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi, Takeda.Support for research projects introduced by the investigator AstraZeneca, Boehringer‑Ingelheim, GlaxoSmithKline, Merck, Takeda. Consulting and advisory boards Astra Zeneca, Novartis, Methapharm. Royalties Co‑author of “Up‑To‑Date”(occupational asthma). Nonprofit grants for production of educational materials Astra‑ Zeneca, Boehringer‑Ingelheim, GlaxoSmithKline, Merck Frosst, Novartis. Conference fees AstraZeneca, GlaxoSmithKline, Merck, Novartis. Support for participation in conferences and meetings Novartis, Takeda. Other participa‑ tions Past president and Member of the Canadian Thoracic Society Respiratory Guidelines Committee; Chair of the Board of Directors of the Global Initiative for Asthma (GINA). Chair of Global Initiative for Asthma (GINA) Guidelines Dis‑ semination and Implementation Committee; Laval University Chair on Knowl‑ edge Transfer, Prevention and Education in Respiratory and Cardiovascular Health; Member of scientific committees for the American College of Chest Physicians, American Thoracic Society, European Respiratory Society and the World Allergy Organization;1st Vice‑President of the Global Asthma Organiza‑ tion “InterAsma”. Dr. Casale reports grants and non‑financial support from Stall‑ ergenes, outside the submitted work. Dr. Cruz reports grants and personal fees from GlaxoSmithKline, personal fees from Boehrinher Ingelheim, AstraZeneca, Novartis, Merk, Sharp & Dohme, MEDA Pharma, EUROFARMA, Sanofi Aventis, outside the submitted work. Dr. Ebisawa reports personal fees from DBV Technologies, Mylan EPD maruho, Shionogi & CO., Ltd., Kyorin Pharmaceuti‑ cal Co., Ltd., Thermofisher Diagnostics, Pfizer, Beyer, Nippon Chemifar, Takeda Pharmaceutical Co., Ltd., MSD, outside the submitted work. Dr. Ivancevich reports personal fees from Euro Farma Argentina, Faes Farma, non‑financial support from Laboratorios Casasco, outside the submitted work. Dr. Haahtela reports personal fees from Mundipharma, Novartis, and Orion Pharma, outside the submitted work. Dr. Klimek reports grants and personal fees from ALK Abelló, Denmark, Novartis, Switzerland, Allergopharma, Germany, Bionorica, Germany, GSK, Great Britain, Lofarma, Italy, personal fees from MEDA, Sweden, Boehringer Ingelheim, Germany, grants from Biomay, Austria, HAL, Netherlands, LETI, Spain, Roxall, Germany, Bencard, Great Britain, outside the submitted work. V.KV has received payment for consultancy from GSK and for lectures from StallergensGreer, Berlin‑CHemie and sponsorship from MYLAN for in the following proffesional training: ARIA masterclass in allergic rhinitis participation. Dr. Larenas Linnemann reports personal fees from GSK, Astra‑ zeneca, MEDA, Boehringer Ingelheim, Novartis, Grunenthal, UCB, Amstrong, Siegfried, DBV Technologies, MSD, Pfizer., grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Chiesi, Boehringer Ingelheim, outside the submitted work. Dr. Mösges reports personal fees from ALK, grants from ASIT biotech, Leti, BitopAG, Hulka, Ursapharm, Optima; personal fees from allergopharma, Nuvo, Meda, Friulchem, Hexal, Servier, Bayer, Johnson&Johnson, Klosterfrau, GSK, MSD, FAES, Stada, UCB, Allergy Therapeutics; grants and personal fees from Bencard, Stallergenes; grants, personal fees and non‑financial support from Lofarma; non‑financial support from Roxall, Atmos, Bionorica, Otonomy, Ferrero; personal fees and non‑financial support from Novartis; Dr. Okamoto reports personal fees from Eizai Co., Ltd., Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, Kyowa Co., Ltd., grants and personal fees from Kyorin Co., Ltd., Tiho Co., Ltd., grants from Yakuruto Co., Ltd., Yamada Bee Farm, outside the submitted work. Dr. Papadopoulos reports grants from Gerolymatos, personal fees from Hal Allergy B.V., Novartis Pharma AG, Menarini, Hal Allergy B.V., outside the submitted work. Dr. Pépin reports grants from AIR LIQUIDE FOUNDATION, AGIR à dom, ASTRA ZENECA, FISHER & PAYKEL, MUTUALIA, PHILIPS, RESMED, VITALAIRE, other from AGIR à dom, ASTRA ZENECA, BOEHRINGER INGEL‑ HEIM, JAZZ PHARMACEUTICAL, NIGHT BALANCE, PHILIPS, RESMED, SEFAM, outside the submitted work. Dr. Pfaar reports grants and personal fees from ALK‑Abelló, Allergopharma Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, grants from Biomay, ASIT Biotech Tools S.A, Laboratorios LETI/LETI Pharma, Anergis S.A., grants from Nuvo, Circassia, Glaxo Smith Kline, personal fees from Novartis Pharma, MEDA Pharma, Mobile Chamber Experts (a GA2LEN Partner), Pohl‑ Boskamp, Indoor Biotechnologies, grants from, outside the submitted work. Dr. Todo‑Bom reports grants and personal fees from Novartis, Mundipharma, GSK Teva Pharma, personal fees from AstraZeneca, grants from Leti, outside the submitted work. Dr. Tsiligianni reports advisory boards from Boehringer Ingelheim and Novartis and a grant from GSK, outside the submitted work. Dr. Wallace reports and Indicates that she is the co‑chair of the Joint Task Force on Practice Parameters, a task force composed of 12 members of the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology. Dr. Waserman reports other from CSL Behring, Shire, AstraZeneca,Teva, Meda, Merck, outside the submitted work. Dr. Zuberbier reports and Organizational affiliations: Commitee member: WHO‑Initiative “Allergic Rhinitis and Its Impact on Asthma”(ARIA). Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI). Head: European Centre for Allergy Research Foundation (ECARF) Secretary General: Global Allergy and Asthma European Network (GA2LEN). Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO).
Sources of information:
Directorio de Producción Científica
Scopus